Johnson Financial Group, Inc. Cellectar Biosciences, Inc. Transaction History

Johnson Financial Group, Inc.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 13, 2021	BUY	$11.8 - $18.2 $11,800 - $18,200	1,000 Added 22.22%	5,500 $7,000
Q1 2021 May 14, 2021	BUY	$15.2 - $25.0 $68,400 - $112,500	4,500 New	4,500 $7,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $12.5M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Johnson Financial Group, Inc. with notifications on news.